{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:36:14Z","timestamp":1781501774185,"version":"3.54.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","fsijournal.org","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Forensic Science International"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.forsciint.2016.03.031","type":"journal-article","created":{"date-parts":[[2016,3,23]],"date-time":"2016-03-23T03:37:20Z","timestamp":1458704240000},"page":"200-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The therapeutic use of cannabinoids: Forensic aspects"],"prefix":"10.1016","volume":"265","author":[{"given":"Francesca","family":"Indorato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Liberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Ledda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunziata","family":"Barbera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.forsciint.2016.03.031_bib0100","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/phar.1187","article-title":"The pharmacologic and clinical effects of medical cannabis","volume":"33","author":"Borgelt","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.forsciint.2016.03.031_bib0105","series-title":"Gazzetta Ufficiale n. 100 del 30 aprile 2013 Supplemento Ordinario Autorizzazione all\u2019immissione in commercio del medicinale per uso umano \u201cSativex\u201d (13A03504)","year":"2013"},{"key":"10.1016\/j.forsciint.2016.03.031_bib0110","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000357427","article-title":"Nabiximols (THC\/CBD Oromucosal Spray, Sativex\u00ae) in clinical practice \u2013 results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity","volume":"71","author":"Flachenecker","year":"2014","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.forsciint.2016.03.031_bib0115","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1177\/1352458510367462","article-title":"Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis","volume":"16","author":"Wade","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.forsciint.2016.03.031_bib0120","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1468-1331.2010.03328.x","article-title":"A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex\u00ae), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis","volume":"18","author":"Novotna","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.forsciint.2016.03.031_bib0125","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/09595230412331289482","article-title":"A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions","volume":"23","author":"Kelly","year":"2004","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.forsciint.2016.03.031_bib0130","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0001-4575(03)00084-8","article-title":"Psychoactive substance use and the risk of motor vehicle accidents","volume":"36","author":"Movig","year":"2004","journal-title":"Accid. Anal. Prev."},{"key":"10.1016\/j.forsciint.2016.03.031_bib0135","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0379-0738(03)00134-8","article-title":"The incidence of drugs in drivers killed in Australian road traffic crashes","volume":"134","author":"Drummer","year":"2003","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.forsciint.2016.03.031_bib0140","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.forsciint.2014.12.018","article-title":"The combined effects of alcohol and cannabis on driving: impact on crash risk","volume":"248","author":"Dubois","year":"2015","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.forsciint.2016.03.031_bib0145","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.drugalcdep.2003.10.008","article-title":"Dose related risk of motor vehicle crashes after cannabis use","volume":"73","author":"Ramaekers","year":"2004","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.forsciint.2016.03.031_bib0150","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/003335491412900409","article-title":"Fatal crashes from drivers testing positive for drugs in the U.S., 1993\u20132010","volume":"129","author":"Wilson","year":"2014","journal-title":"Public Health Rep."},{"key":"10.1016\/j.forsciint.2016.03.031_bib0155","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/dta.1517","article-title":"Comparison between self-report of cannabis use and toxicological detection of THC\/THCCOOH in blood and THC in oral fluid in drivers in a roadside survey","volume":"6","author":"Van der Linden","year":"2014","journal-title":"Drug Test Anal."},{"key":"10.1016\/j.forsciint.2016.03.031_bib0160","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00228-012-1441-0","article-title":"A phase I study to assess the single and multiple dose pharmacokinetics of THC\/CBD oromucosal spray","volume":"69","author":"Stott","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.forsciint.2016.03.031_bib0165","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/jat\/19.6.419","article-title":"A reliable method for the detection, confirmation, and quantitation of cannabinoids in blood","volume":"19","author":"Goodall","year":"1995","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.forsciint.2016.03.031_bib0170","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/bms.1200090103","article-title":"Single dose kinetics of deuterium labelled delta 1-tetrahydrocannabinol in heavy and light cannabis users","volume":"1","author":"Ohlsson","year":"1982","journal-title":"Biomed. Mass Spectrom."},{"key":"10.1016\/j.forsciint.2016.03.031_bib0175","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/TCRM.S1928","article-title":"Cannabinoids in the management of difficult to treat pain","volume":"4","author":"Russo","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.forsciint.2016.03.031_bib0180","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/cbdv.200790152","article-title":"Human cannabinoid pharmacokinetics","volume":"8","author":"Huestis","year":"2007","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.forsciint.2016.03.031_bib0185","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/2193-1801-2-236","article-title":"A phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC\/CBD oromucosal spray in healthy volunteers","volume":"2","author":"Stott","year":"2013","journal-title":"Springerplus"},{"key":"10.1016\/j.forsciint.2016.03.031_bib0190","doi-asserted-by":"crossref","first-page":"15A","DOI":"10.1155\/2005\/242516","article-title":"Pharmacokinetics of cannabinoids","volume":"10","author":"McGilveray","year":"2005","journal-title":"Pain Res. Manag."}],"container-title":["Forensic Science International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0379073816301177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0379073816301177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T18:20:00Z","timestamp":1567707600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0379073816301177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":19,"alternative-id":["S0379073816301177"],"URL":"https:\/\/doi.org\/10.1016\/j.forsciint.2016.03.031","relation":{},"ISSN":["0379-0738"],"issn-type":[{"value":"0379-0738","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The therapeutic use of cannabinoids: Forensic aspects","name":"articletitle","label":"Article Title"},{"value":"Forensic Science International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.forsciint.2016.03.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}